In the first three months of the year, Heron's approved meds Cinvanti and Sustol, each of which address one of the primary mechanisms of chemo-induced nausea and vomiting, generated $18.5 million and $1.5 million, respectively. All told, the company's oncology franchise reeled in $20 million for the period, versus $25.4 million in 2020's first quarter.